NCT02456675: INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma |
|
|
| Terminated | 2 | 8 | NA | INCB040093 Monotherapy, INCB040093, itacitinib, INCB039110 | Incyte Corporation | Refractory Hodgkin Lymphoma, Recurrent Adult Hodgkin's Lymphoma | 12/16 | 12/16 | | |
| Active, not recruiting | 1/2 | 23 | US | Itacitinib, INCB039110, Everolimus, Afinitor | University of Pennsylvania | Classical Hodgkin Lymphoma | 10/24 | 06/27 | | |
